The non-randomized esketamine KAP trial cannot isolate psychotherapy from drug effect, and methodologists will publicly call for controlled designs within 10 weeks.

When a study combines a drug with therapy but doesn't include a comparison group (some people getting only the drug, only the therapy, or neither), there's no way to know which part is helping. Neuroscientists and clinical researchers are expected to point this out publicly, calling for a study that properly isolates each element. Without that, no one — including regulators — can responsibly recommend the combined treatment.

You cannot attribute adjunctive benefit without randomization and a comparator arm. The neuroscience community will flag this confound rapidly.